A Forkhead Box ProteinC2 Inhibitor: Targeting Epithelial-Mesenchymal Transition and Cancer Metastasis

Maria Castaneda, Luxi Chen, Lagnajeet Pradhan, Shichang Li, Ruba Zein, Yeongju Lee, Hyun-Suk Lim, Hyun Joo Nam, Jiyong Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The epithelial-mesenchymal transition (EMT) has been suggested as a new target for therapeutic intervention of metastatic cancer. Forkhead box proteinC2 (FOXC2) is known to be necessary for initiating and maintaining EMT, and therefore bestows on cancer cells metastatic and cancer stem cell (CSC)-like phenotypes, allowing cells to acquire higher motility, invasiveness, self-renewal, and therapy resistance. Here, we describe the first inhibitor of FOXC2, MC-1-F2. MC-1-F2 was able to induce cadherin switching and reverse EMT through the degradation of FOXC2 and blocking of its nuclear localization. In addition, MC-1-F2 was very effective in inhibiting cancer cell migration and invasion. As the first small-molecule inhibitor of FOXC2 and the first compound targeting EMT-associated transcription factor, MC-1-F2 will pave the way for a new anticancer therapeutic agent targeting metastatic cancer and help to elucidate the network of EMT signaling pathways.

Original languageEnglish (US)
JournalChemBioChem
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Epithelial-Mesenchymal Transition
Cells
Neoplasm Metastasis
Cadherins
Stem cells
Neoplasms
Transcription Factors
Degradation
Molecules
Neoplastic Stem Cells
Antineoplastic Agents
Cell Movement
Therapeutics
Phenotype

Keywords

  • Cancer metastasis
  • Combinatorial chemistry
  • Drug discovery
  • Epithelial-mesenchymal transition
  • Transcription factor

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Organic Chemistry

Cite this

Castaneda, M., Chen, L., Pradhan, L., Li, S., Zein, R., Lee, Y., ... Lee, J. (Accepted/In press). A Forkhead Box ProteinC2 Inhibitor: Targeting Epithelial-Mesenchymal Transition and Cancer Metastasis. ChemBioChem. https://doi.org/10.1002/cbic.201800022

A Forkhead Box ProteinC2 Inhibitor : Targeting Epithelial-Mesenchymal Transition and Cancer Metastasis. / Castaneda, Maria; Chen, Luxi; Pradhan, Lagnajeet; Li, Shichang; Zein, Ruba; Lee, Yeongju; Lim, Hyun-Suk; Nam, Hyun Joo; Lee, Jiyong.

In: ChemBioChem, 01.01.2018.

Research output: Contribution to journalArticle

Castaneda, Maria ; Chen, Luxi ; Pradhan, Lagnajeet ; Li, Shichang ; Zein, Ruba ; Lee, Yeongju ; Lim, Hyun-Suk ; Nam, Hyun Joo ; Lee, Jiyong. / A Forkhead Box ProteinC2 Inhibitor : Targeting Epithelial-Mesenchymal Transition and Cancer Metastasis. In: ChemBioChem. 2018.
@article{3b1d28302777464b9d00da876f4426f7,
title = "A Forkhead Box ProteinC2 Inhibitor: Targeting Epithelial-Mesenchymal Transition and Cancer Metastasis",
abstract = "The epithelial-mesenchymal transition (EMT) has been suggested as a new target for therapeutic intervention of metastatic cancer. Forkhead box proteinC2 (FOXC2) is known to be necessary for initiating and maintaining EMT, and therefore bestows on cancer cells metastatic and cancer stem cell (CSC)-like phenotypes, allowing cells to acquire higher motility, invasiveness, self-renewal, and therapy resistance. Here, we describe the first inhibitor of FOXC2, MC-1-F2. MC-1-F2 was able to induce cadherin switching and reverse EMT through the degradation of FOXC2 and blocking of its nuclear localization. In addition, MC-1-F2 was very effective in inhibiting cancer cell migration and invasion. As the first small-molecule inhibitor of FOXC2 and the first compound targeting EMT-associated transcription factor, MC-1-F2 will pave the way for a new anticancer therapeutic agent targeting metastatic cancer and help to elucidate the network of EMT signaling pathways.",
keywords = "Cancer metastasis, Combinatorial chemistry, Drug discovery, Epithelial-mesenchymal transition, Transcription factor",
author = "Maria Castaneda and Luxi Chen and Lagnajeet Pradhan and Shichang Li and Ruba Zein and Yeongju Lee and Hyun-Suk Lim and Nam, {Hyun Joo} and Jiyong Lee",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cbic.201800022",
language = "English (US)",
journal = "ChemBioChem",
issn = "1439-4227",
publisher = "Wiley-VCH Verlag",

}

TY - JOUR

T1 - A Forkhead Box ProteinC2 Inhibitor

T2 - Targeting Epithelial-Mesenchymal Transition and Cancer Metastasis

AU - Castaneda, Maria

AU - Chen, Luxi

AU - Pradhan, Lagnajeet

AU - Li, Shichang

AU - Zein, Ruba

AU - Lee, Yeongju

AU - Lim, Hyun-Suk

AU - Nam, Hyun Joo

AU - Lee, Jiyong

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The epithelial-mesenchymal transition (EMT) has been suggested as a new target for therapeutic intervention of metastatic cancer. Forkhead box proteinC2 (FOXC2) is known to be necessary for initiating and maintaining EMT, and therefore bestows on cancer cells metastatic and cancer stem cell (CSC)-like phenotypes, allowing cells to acquire higher motility, invasiveness, self-renewal, and therapy resistance. Here, we describe the first inhibitor of FOXC2, MC-1-F2. MC-1-F2 was able to induce cadherin switching and reverse EMT through the degradation of FOXC2 and blocking of its nuclear localization. In addition, MC-1-F2 was very effective in inhibiting cancer cell migration and invasion. As the first small-molecule inhibitor of FOXC2 and the first compound targeting EMT-associated transcription factor, MC-1-F2 will pave the way for a new anticancer therapeutic agent targeting metastatic cancer and help to elucidate the network of EMT signaling pathways.

AB - The epithelial-mesenchymal transition (EMT) has been suggested as a new target for therapeutic intervention of metastatic cancer. Forkhead box proteinC2 (FOXC2) is known to be necessary for initiating and maintaining EMT, and therefore bestows on cancer cells metastatic and cancer stem cell (CSC)-like phenotypes, allowing cells to acquire higher motility, invasiveness, self-renewal, and therapy resistance. Here, we describe the first inhibitor of FOXC2, MC-1-F2. MC-1-F2 was able to induce cadherin switching and reverse EMT through the degradation of FOXC2 and blocking of its nuclear localization. In addition, MC-1-F2 was very effective in inhibiting cancer cell migration and invasion. As the first small-molecule inhibitor of FOXC2 and the first compound targeting EMT-associated transcription factor, MC-1-F2 will pave the way for a new anticancer therapeutic agent targeting metastatic cancer and help to elucidate the network of EMT signaling pathways.

KW - Cancer metastasis

KW - Combinatorial chemistry

KW - Drug discovery

KW - Epithelial-mesenchymal transition

KW - Transcription factor

UR - http://www.scopus.com/inward/record.url?scp=85047737224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047737224&partnerID=8YFLogxK

U2 - 10.1002/cbic.201800022

DO - 10.1002/cbic.201800022

M3 - Article

C2 - 29577543

AN - SCOPUS:85047737224

JO - ChemBioChem

JF - ChemBioChem

SN - 1439-4227

ER -